This exceptional growth comes despite experiencing its lowest levels since the COVID shock earlier in the year, according to BCG’s annual Global M&A Report 2025 released today ... BCG’s M&A ...
This exceptional growth comes despite experiencing its lowest levels since the Covid shock earlier in the year, according to BCG's annual GlobalM&AReport 2025 released Monday ... BCG's M&A Sentiment ...
BCG, which brought on 1,000 employees last year, has ramped up hiring technologists since launching its tech and AI arm, BCG X, in late 2022 ... firm," said Sylvain Duranton, GlobalLeader of BCG X.
The key Bahrain findings of BCG’s new proprietary analysis are. ... wealth managers lies in their ability to seize these opportunities,” added Lukasz Rey, Managing Director and Partner at BCG.
QUILT-3.032 (NCT03022825) is a registrational, open-label, single-arm multicenter phase 2/3 trial of ANKTIVA plus BCG in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Lukasz Rey, Managing Director and Partner at BCG, said, “The key to success today is no longer merely about gaining market exposure or hiring senior bankers; it’s about fostering internal growth.